Cargando…

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)

Oritavancin displayed potent and stable activity (MIC(90) range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalhaes, Cecilia G., Sader, Helio S., Streit, Jennifer M., Castanheira, Mariana, Mendes, Rodrigo E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Epidemiology and Surveillance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846398/ https://www.ncbi.nlm.nih.gov/pubmed/34807761 http://dx.doi.org/10.1128/AAC.01667-21

Ejemplares similares

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
por: Carvalhaes, Cecilia G., et al.
Publicado: (2020)

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
por: Diekema, Daniel J., et al.
Publicado: (2019)

129. Antimicrobial Activity of Ceftazidime–avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017–2018)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)
por: Sader, Helio S., et al.
Publicado: (2022)

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
por: Arends, S. J. Ryan, et al.
Publicado: (2023)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

734. Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
por: Sader, Helio S, et al.
Publicado: (2020)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

37. Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016–2019)
por: Sader, Helio S, et al.
Publicado: (2020)

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program
por: Pfaller, Michael A., et al.
Publicado: (2017)

A Systematic Review and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections among Hospitalized Patients in Africa and Asia
por: Marchello, Christian S., et al.
Publicado: (2019)

Increasing proportion of vancomycin-resistance among enterococcal bacteraemias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018
por: Piezzi, Vanja, et al.
Publicado: (2020)

1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)

Nationwide Surveillance and Molecular Characterization of Critically Drug-Resistant Gram-Negative Bacteria: Results of the Research University Network Thailand Study
por: Yungyuen, Thitiya, et al.
Publicado: (2021)

200. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against AmpC Hyperproducing Enterobacterales and P. aeruginosa Collected from United States (US) Medical Centers (2016-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Results from the Canadian Nosocomial Infection Surveillance Program on Carbapenemase-Producing Enterobacteriaceae, 2010 to 2014
por: Mataseje, Laura F., et al.
Publicado: (2016)

Molecular Epidemiology of Emerging Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter pittii in Taiwan, 2010 to 2014
por: Chen, Feng-Jui, et al.
Publicado: (2019)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
por: Pfaller, Michael A., et al.
Publicado: (2018)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)
por: Pfaller, M. A., et al.
Publicado: (2022)

Eight-year trends in the relative isolation frequency and antimicrobial susceptibility among bloodstream isolates from Greek hospitals: data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance – WHONET-Greece, 2010 to 2017
por: Polemis, Michalis, et al.
Publicado: (2020)

1472. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019)
por: Sader, Helio S, et al.
Publicado: (2020)

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19)
por: Sader, Helio S, et al.
Publicado: (2021)

1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible Streptococcus pneumoniae from the United States (2008-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ju6283j9m17kg2fij4k6876gq